{"page":{"totalFilteredElements":348},"studies":[{"active":true,"description":"RNA Disruption Assay (RDA) Breast cancer Response EValuation for Individualized TherapY-02 (BREVITY-02)","eudractNumber":null,"id":7611,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03524430","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-03-26T11:53:32+01:00","shortTitle":"BREVITY-02","therapeutical":false,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"
PiR-HoP aimed at establishing a multi-site prospective clinical registry for two specific groups of prostate cancer patients, who present a particular clinical challenge:
 the oligometastatic prostate cancer
 the high risk prostate cancer in young patients
","eudractNumber":null,"id":11017,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-08-02T08:53:09+02:00","shortTitle":"BZKF- PiR-hoP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"PARP-Inhibitor Reinduktion beim rezidivierenden Ovarialkarzinom: Versorgungsrealität in \nBayern, translationale Biomarker und klinische Ergebnisse","eudractNumber":null,"id":9729,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-10-14T10:33:31+02:00","shortTitle":"BZKF-OVAR-1","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A Phase 2 Study to Evaluate the Efficacy and Safety of\nBelzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced\nPheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

","eudractNumber":"2020-005028-13","id":7072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04924075","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-03-01T14:45:17+01:00","shortTitle":"Belzutifan/MK-6482 for the treatment of PPGL or pNET","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Beobachtung der Medizinischen Rehabilitation auf die Lebensqualität von Patientinnen und Patienten mit chronisch myeloischer Leukämie (CML)

Registriernummer DRKS00005385

","eudractNumber":null,"id":6558,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2013-12-23T08:57:59+01:00","shortTitle":"Beobachtung der Medizinischen Rehabilitation auf die Lebensqualität von Patientinnen und Patienten mit chronisch myeloischer Leukämie (CML)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht interventionelle Langzeitstudie (NIS) zum klinischen Einsatz von Biotest IVIGs in verschiedenen Indikationen. ","eudractNumber":null,"id":7451,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-09-01T11:16:22+02:00","shortTitle":"Biotest NIS-020 (IVIG)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"LiverageTM - A randomised, double-blind, placebo-controlled, multicentre, phase III trial evaluating long-term efficacy and safety off survodutide weekly injections in adult particpants with non-cirrhotic, non-alcoholic steatohepatitis - metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis","eudractNumber":"2024-513739-25-00","id":11353,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06632444","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T14:22:17+02:00","shortTitle":"Boehringer Ingelheim 1404-0044","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"LiverageTM - A phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis-metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis","eudractNumber":"2024-513741-36-00","id":11352,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06632457","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T09:50:33+02:00","shortTitle":"Boehringer Ingelheim 1404-0064","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Hirnmetastasen im Brustkrebs-Netzwerk Deutschland","eudractNumber":null,"id":7905,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-01-01T11:16:19+01:00","shortTitle":"Brain Metastases in Breast Cancer Network - BMBC (GBG 79)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive und Retrospektive Registerstudie der German Breast Group (GBG) Zur Diagnostik und Therapie des Mammakarzinoms in der Schwangerschaft mit jungen, nicht schwangeren Patientinnen (<40Jahre) als Vergleichskohorte","eudractNumber":null,"id":6193,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT00196833","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-01-01T08:20:45+01:00","shortTitle":"Breast Cancer in Pregnancy (BCP)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}